Skip to main content

11 Result(s)

within Julianne L. Holleran Remove this filter

and

  1. No Access

    Article

    Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions

    This study aimed at characterizing indotecan population pharmacokinetics and explore the indotecan–neutropenia relationship in patients with solid tumors.

    Jan H. Beumer, Benjamin C. Kennard… in Cancer Chemotherapy and Pharmacology (2023)

  2. No Access

    Article

    Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker

    Carboplatin dose is calculated based on kidney function, commonly estimated with imperfect creatinine-based formulae. Iohexol is used to measure glomerular filtration rate (GFR) and allows calculation of a mor...

    Anand Joshi, Jianxia Guo, Julianne L. Holleran… in Cancer Chemotherapy and Pharmacology (2020)

  3. No Access

    Article

    Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors

    Indenoisoquinolines are non-camptothecin topoisomerase I (TopI) inhibitors that overcome the limitations of camptothecins: chemical instability and camptothecin resistance. Two dosing schedules of the novel in...

    Shivaani Kummar, Alice Chen, Martin Gutierrez… in Cancer Chemotherapy and Pharmacology (2016)

  4. No Access

    Article

    A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis

    Very little is known about the pharmacokinetics of chemotherapeutic agents in patients also being treated with continuous ambulatory peritoneal dialysis. We sought to evaluate the pharmacokinetics of cisplati...

    Jennifer R. Eads, Jan H. Beumer, Lavinia Negrea… in Cancer Chemotherapy and Pharmacology (2016)

  5. No Access

    Article

    Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans

    5-Fluoro-2′-deoxycytidine (FdCyd; NSC48006), a fluoropyrimidine nucleoside inhibitor of DNA methylation, is degraded by cytidine deaminase (CD). Pharmacokinetic evaluation was carried out in cynomolgus monkeys...

    Julianne L. Holleran, Jan H. Beumer… in Cancer Chemotherapy and Pharmacology (2015)

  6. No Access

    Article

    Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs

    NSC 743400 is a novel synthetic indenoisoquinoline analog under development as an anticancer agent. It is a potent topoisomerase I inhibitor with potential therapeutic advantages over FDA-approved camptothecin...

    Miguel Muzzio, Shu-Chieh Hu, Julianne L. Holleran… in Cancer Chemotherapy and Pharmacology (2015)

  7. No Access

    Article

    Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)

    Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and ...

    Jan H. Beumer, Kouros Owzar, Lionel D. Lewis… in Cancer Chemotherapy and Pharmacology (2014)

  8. No Access

    Article

    Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice

    Cytidine drugs, such as gemcitabine, undergo rapid catabolism and inactivation by cytidine deaminase (CD). 3,4,5,6-tetrahydrouridine (THU), a potent CD inhibitor, has been applied preclinically and clinically ...

    Jan H. Beumer, Julie L. Eiseman, Judith A. Gilbert… in Cancer Chemotherapy and Pharmacology (2011)

  9. No Access

    Article

    Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance

    17-DMAG is a hydrophilic derivative of the molecular chaperone inhibitor 17-(allylamino)-17-demethoxygeldanamycin (17-AAG; NSC-330507), which is currently being evaluated for the treatment of cancer in clinica...

    Elizabeth R. Glaze, Amy L. Lambert… in Cancer Chemotherapy and Pharmacology (2005)

  10. No Access

    Protocol

    Tumor-Specific Metastasis to Lung Using Reporter Gene-Tagged Tumor Cells

    The lung offers circulating tumor cells—after their initial development as primary tumors and their selection for metastasis to other organs of patients—several optimal conditions for survival and progression ...

    Lloyd A. Culp, Wen-Chang Lin, Nanette Kleinman, Julianne L. Holleran… in Lung Cancer (2003)

  11. No Access

    Article

    Differential experimental micrometastasis to lung, liver, and bone with lacZ-tagged CWR22R prostate carcinoma cells

    LacZ-tagged human prostate carcinoma CWR22Rv1 cells metastasize spontaneously to lung, liver, and bone from subcutaneous primary tumors in athymic nude mice; these organs are ‘natural’ targets of metastasis for ...

    Julianne L. Holleran, Carson J. Miller… in Clinical & Experimental Metastasis (2002)